Reports

Document Sample
Reports Powered By Docstoc
					                                                                                    Reports



Biobanking for Medical R&D: Technology and Market 2010-2025

Table of Contents

1. Executive Summary

1.1 Summary Points
1.2 Aims, Scope and Format of this Report
1.2.1 Speculative Aspects of Assessing the Biobanking Market
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods

2. Introduction to Biobanking

2.1 Biobanking
2.1.1 Processes Involved in Biobanking
2.2 Biobanks: A Two-fold Character
2.3 Key Features
2.4 Classification of Biobanks
2.4.1 Volunteer Groups
2.4.1.1 Population-based Biobanks
2.4.1.2 Disease-oriented Biobanks
2.4.2 Ownership or Funding Structure
2.5 Guidelines and Standards
2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research
2.5.2 Industry Standards for Biobanks
2.5.3 Biobanking Processes Governed by Guidelines
2.6 Laws and Regulations for Biobank-based Research

3. Biobanking and the Pharmaceutical Industry

3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry
3.1.1 Research and Drug Development
3.1.1.1 Understanding Disease Pathways
3.1.1.2 Drug Discovery
3.1.1.3 Biomarker Discovery
3.1.2 Therapeutics
3.1.3 Clinical Trials
3.2 Biobanks Operated by Pharmaceutical Companies

4. Biobanking: Associated Market (Systems, Software, Consumables, and
Services Associated with Biobanking)

4.1 Systems/ Technologies
                  PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                              Online Store: www.pipelinereview.com
                                                                                    Reports

4.1.1 Automated Liquid Handling
4.1.1.1 Frozen Aliquotting: New Technology in Development
4.1.2 Storage
4.1.2.1 Ultra-low Temperature Freezing
4.1.2.2 Room-Temperature Storage
4.1.3 RFID and Tagging Technologies
4.2 Software
4.2.1 Laboratory Information Management System (LIMS)
4.2.1.1 LIMS Functions
4.3 Consumables
4.4 Services

5. Global Biobanking Market, 2010-2025

5.1 Current State of the Biobanking Market
5.2 Geographical Footprint
5.3 Growing Demand for Biobank Resources
5.4 Revenue Forecast for Total Biobanking Market
5.4.1 Scope and Limitations
5.4.2 Biobanking Market, 2010-2025
5.5 Commercial Biobanks: New Resources for Research

6. Human Tissue Banking Market

6.1 Revenue Forecast for Total Human Tissue Banking Market, 2010-2025
6.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank,
2010-2025
6.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets,
2010-2025
6.4 Commercial Participants in the Human Tissue Banking Market
6.4.1 Business Models of Companies in the Biobanking Market
6.4.2 Tissue Solutions Ltd.
6.4.2.1 Overview
6.4.2.2 Global Presence
6.4.2.3 Products and Services
6.4.2.3.1 Banked Samples
6.4.2.3.2 Prospective Samples
6.4.2.3.3 Fresh Samples
6.4.2.3.4 Freshly Isolated and Primary Cells
6.4.2.3.5 Services
6.4.2.4 Strengths and Capabilities
6.4.2.5 Future Outlook
6.4.3 Asterand Plc.
6.4.3.1 Overview
6.4.3.2 Global Presence
6.4.3.3 Products and Services
6.4.3.3.1 XpressBANK
6.4.3.3.2 ProCURE
6.4.3.3.3 PhaseZERO


                  PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                              Online Store: www.pipelinereview.com
                                                                                    Reports
6.4.3.3.4 BioMAP
6.4.3.4 Asterand: Providing Barriers for New Market Entrants?
6.4.3.5 Financial Performance
6.4.3.6 Future Outlook

7. Stem Cell Banking

7.1 Overview
7.2 Revenue Forecast for Total Stem Cell Banking, 2010-2025
7.3 Stem Cell Banks for Research: High Growth Possible
7.4 Umbilical Cord Blood Banking for Stem Cells
7.4.1 Biological Insurance: Private Blood Banking
7.4.2 Umbilical Cord Banking: The Controversies
7.4.2.1 US Oversight of Cord Blood Stem Cells
7.4.3 Companies in the Field
7.4.3.1 Cord Blood America: Looking Towards the Chinese Market
7.4.3.2 ViaCord: 145,000 Blood Units in Storage
7.4.3.3 Cryo-Cell International: The First Cord Blood Bank
7.4.3.4 Stem Cell Authority: Exclusive Stem Cells
7.4.3.5 LifebankUSA: Placenta-Cord Banking
7.5 Gene/ DNA Banking

8. Industry Trends

8.1 Automated Biobanking
8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in
Biobanking
8.1.2 Addressing Sample Storage and Tracking Issues
8.2 Green Banking
8.3 Creation of National Biobanks
8.4 HIPAA Amendments

9. SWOT Analysis of the Biobanking Sector

9.1 Strengths
9.1.1 Wealth of Information for Genetic Research
9.1.2 Potential to Change Treatments
9.1.3 Many Governments Support Biobanking
9.2 Weaknesses
9.2.1 Quality Concerns for Existing Biospecimen Collections
9.2.2 Lack of Standardisation and Harmonisation of Best Practices
9.2.3 Limited Sharing and Linkage of Biobanks
9.3 Opportunities
9.3.1 Genome-Wide Association Studies (GWAS)
9.3.2 Personalised Medicine
9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach
9.4 Threats
9.4.1 Ethical and Regulatory Issues
9.4.1.1 Limitations of Informed Consent in Biobanking
9.4.1.2 Confidentiality and Security to Prevent Improper Use


                  PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                              Online Store: www.pipelinereview.com
                                                                                    Reports
9.4.2 Social and Cultural Issues
9.4.3 Ownership Issues
9.4.4 Funding

10. Expert Opinion

10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions
10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry
10.1.2 On Commercial Aspects of Biobanking
10.1.3 On the Business of Tissue Solutions
10.1.4 On the Attractiveness of Human Tissue Banking
10.1.5 On the Future of the Biobanking Market

11. Conclusions

11.1   Biobanking for Research and Therapeutics
11.2   Biobanking: The Future for Drug Discovery and Personalised Medicine?
11.3   Commercial Drivers of the Biobanking Market
11.4   The Sector Has Marked Challenges, but Many Opportunities for Growth

List of Tables

Table 2.1 Prominent Population-based Biobanks, 2010
Table 2.2 Prominent Disease-oriented Biobanks, 2010
Table 2.3 Some Guidelines and Recommendations for Biobanks, 2010
Table 2.4 Laws and Regulations for Biobank-based Research, Consent
Requirements, and Privacy/ Data Protection, 2010
Table 3.1 Some Pharmaceutical and Biotechnology Companies with In-house
Biobanks, 2010
Table 4.1 Prominent Companies in the Automated Liquid Handling Market, 2010
Table 4.2 Prominent Companies in Ultra-low Temperature Freezer Market, 2010
Table 4.3 Prominent LIMS Vendors, 2010
Table 4.4 Prominent Consumables Suppliers for Biobanking, 2010
Table 4.5 Prominent Biorepository Service Providers, 2010
Table 5.1 Estimated Number of Biobanks in Europe, 2010
Table 5.2 Overall Biobanking Market: Revenue Forecast, 2010-2017
Table 5.3 Overall Biobanking Market: Revenue Forecast, 2018-2025
Table 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2017
Table 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2018-2025
Table 6.3 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank,
2010-2017
Table 6.4 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank,
2018-2025
Table 6.5 Human Tissue Banking Market: Revenue Forecasts for Leading National
Markets, 2010-2025
Table 6.6 Leading Companies in the World Biobanking Market, 2010
Table 6.7 Asterand: Revenue by Segment, 2008 and 2009
Table 6.8 Asterand: Revenue by Geographical Area, 2008 and 2009
Table 7.1 Stem Cell Banking: Revenue Forecast, 2010-2017
Table 7.2 Stem Cell Banking: Revenue Forecast, 2018-2025


                  PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                              Online Store: www.pipelinereview.com
                                                                                     Reports
Table   7.3   Prominent Stem Cell Banks Serving the Research Community, 2010
Table   7.4   Prominent Companies in the Cord Blood Banking Market, 2010
Table   9.1   SWOT Analysis of the Biobanking Sector, 2010
Table   9.2   Information for a Biobank Donor, 2010

List of Figures

Figure 2.1 Processes Involved in Biobanking, 2010
Figure 2.2 Classification of Biobanks, 2010
Figure 3.1 Biobanking and Pharmaceutical Development, 2010
Figure 4.1 Biobanking Industry: Value Chain Model, 2010
Figure 4.2 Functions of LIMS, 2010
Figure 5.1 Overall Biobanking Market: Revenue Forecast, 2010-2025
Figure 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2025
Figure 6.2 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank,
2010-2025
Figure 6.3 Human Tissue Banking: Market Shares by Type of Biobank, 2010
Figure 6.4 Human Tissue Banking: Market Shares by Type of Biobank, 2025
Figure 6.5 Human Tissue Banking: Market Shares for Leading National Markets,
2010
Figure 6.6 Human Tissue Banking: Market Shares for Leading National Markets,
2015
Figure 6.7 Human Tissue Banking: Market Shares for Leading National Markets,
2020
Figure 6.8 Human Tissue Banking: Market Shares for Leading National Markets,
2025
Figure 6.9 Commercial Sourcing of Biological Samples, 2010
Figure 6.10 Commercial Banking of Biological Samples, 2010
Figure 6.11 Asterand: Revenues, 2008 and 2009
Figure 6.12 Asterand: Revenue Shares by Region of Destination, 2009
Figure 6.13 Asterand: Revenue Shares by Region of Origin, 2009
Figure 7.1 Stem Cell Banking: Revenue Forecast, 2010-2025


Companies Listed

Abcellute
Abgene
Adnexus Therapeutics
AFNOR Groupe
AKH Biobank
AlloSource
American National Bioethics Advisory Commission
American Type Culture Collection
Amgen
Analytical Biological Services
ARCH Venture Partners
Asterand
Asterand UK Limited
Asterand


                   PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                               Online Store: www.pipelinereview.com
                                                                                    Reports
AstraZeneca
Australasian Biospecimen Network (ABN)
Autoscribe
AXM Pharma
Bayer-Schering
Beckman Coulter
Biobank Ireland Trust
Biobank Japan
Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)
BioFortis
Biogen Idec
BioLife Solutions
Biomatrica
Biopta
BioRep
BioSeek
BioServe
BioStorage LLC
BioStorage Technologies
BrainNet Europe
Caliper LifeSciences
Canadian Partnership for Tomorrow
CARTaGENE
Cellgene Corporation
Cells4Health
Chemagen
CLB/ Amsterdam Medical Center
CorCell
Cord Blood America
Cord Blood Registry
CordLife
Cordon Vital (CBR)
Coriell Institute for Medical Research
Council of Europe (CoE)
Covance
Cryo Bio System
Cryo-Cell International
Cryometrix
Cryo-Save
Cureline
Cybrdi
Danubian Biobank Foundation
deCODE Genetics
Department of Health (DoH)
Department of Transportation (DOT)
Draper Laboratory
EGeen
Eli Lilly
Eolas Biosciences
Estonian Genome Project


                  PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                              Online Store: www.pipelinereview.com
                                                                                    Reports

EuroBioBank
European Commission (EC)
European Health Risk Monitoring (EHRM)
European Medicines Agency (EMA/EMEA)
European Union Group on Ethics (EGE)
Fisher BioServices
Fondazione I.R.C.C.S. Istituto Neurologico C. Besta
Food and Drug Administration (US FDA)
Foundation for the National Institutes of Health
Fundación Istituto Valenciano de Oncología
Fundeni Clinical Institute
Genentech
Generation Scotland
GeneSaver
GeneSys
Genetic Association Information Network (GAIN)
Genizon Biosciences
Genome Quebec Biobank
GenomEUtwin
Genomic Studies of Latvian Population
GenVault
German Dementia Competence Network
GlaxoSmithKline (GSK)
H. Lee Moffitt Cancer Center and Research Institute
Hamilton
Hopital Necker Paris – Necker DNA Bank
Human Tissue Authority (HTA)
Hungarian Biobank
HUNT, Norway
ILSBio LLC
Inbiobank
Indivumed
INMEGEN
Institut National de la Santé et de la Recherche Médicale (INSERM)
Integrated BioBank of Luxembourg
International Agency for Research on Cancer (IARC)
International Air Transport Association (IATA)
International Organization for Standardization (ISO)
International Society for Biological and Environmental Repositories (ISBER)
International Stem Cell Corporation
Kaiser Permanente
KORA-gen
LabVantage Solutions
LabWare
Leiden University Medical Center
LifebankUSA
LifeGene
LifeStem
Malaysian Cohort Project


                  PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                              Online Store: www.pipelinereview.com
                                                                                    Reports
Matrical Biosciences
Matrix
Medical Research Council (MRC)
Medical University of Gdansk
Merck & Co.
Merck Sharp & Dohme Limited (MSD)
Merck-Serono
Micronic
Milennium (Takeda Oncology Company)
MVE-Chart
National Cancer Institute (NCI)
National DNA Bank (US)
National Human Genome Research Institute (NHGRI)
National Institute of Environmental Health
National Institutes of Health (NIH)
National Public Health Institute
National Research Ethics Service (NRES)
NeoCodex
NeoStem
Neuromuscular Bank of Tissues and DNA Samples
New Brunswick Scientific
NEXUS Biosystems
Northwest Regional Development Agency
Novacare Bio-Logistics
Novartis
NUgene Project
Ocimum Biosolutions
Office of Biorepositories and Biospecimen Research (OBBR)
OnCore UK
Organisation for Economic Co-operation and Development (OECD)
OriGene
Oxagen
Pacific Bio-Material Management
PathServe
Perkin Elmer
Pfizer
Pharmagene Laboratories Trustees Limited
Polaris Ventures
Pop-Gen (University Hospital Schleswig-Holstein)
PrecisionMed
Prevention Genetics
ProMedDx
Promoting Harmonisation of Epidemiological Biobanks in Europe (PHOEBE)
ProteoGenex
Public Population Projects in Genomics (P3G Consortium)
Qiagen
RAND Corporation
REMP
Reproductive Genetics Institute (RGI)



                  PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                              Online Store: www.pipelinereview.com
                                                                                    Reports

Research Centre of Vascular Diseases, University of Milan
Rhode Island BioBank, Brown University
Roche
RTS Life Science
Saga Investments LLC
Sanofi-Aventis
SANYO Biomedical
Scottish Government
Seattle Genetics
SeqWright DNA Technology Services
SeraCare Life Sciences
Singapore Tissue Network
StarLIMS
Steelgate
Stem Cell Authority
Stem Cells for Safer Medicine (SC4SM)
Stem Cells Research Forum of India
Stemride International
Taiwan Biobank
Taizhou Biobank
TAP
Tecan
The Automation Partnership
The Sorenson Molecular Genealogy Foundation (SMGF)
Thermo Fisher Scientific
Tissue Solutions
Titan Pharmaceuticals
Trinity Biobank
Tumorothèque Necker-Entants Malades
UK Biobank
UK Stem Cell Bank
UmanGenomics
Umeå University
University Hospital Angers
University Medical Center Gent
University of Massachusetts Stem Cell Bank
University of Tuebingen, Department of Medical Genetics
US Biomax
Västerbotten County Council
ViaCord
Wellcome Trust
Wellcome Trust Case-Control Consortium (WTCCC)
Western Australian Genome Health Project
Wheaton Science International
Wisconsin International Stem Cell (WISC) Bank
World Health Organization (WHO)




                  PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91
                      98 | Email info@lamerie.com | Internet www.lamerie.com

                              Online Store: www.pipelinereview.com

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:16
posted:8/18/2011
language:English
pages:9